Satish Misra, MD
Cardiovascular Disease · Charlotte, NCNPI 1669616967
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Boston Scientific at 37.9% of the total. 2025 is the largest year on record at $19,331, more than ten times the $571 reported in 2019. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $182.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$24K
- Medtronic$15K
- Siemens Medical Solutions USA, Inc.$6K
- Biosense Webster, Inc.$5K
- Philips North America LLC$5K
- Abbott$4K
- plus $5K from 13 others
Across 16 payments — averaging $3646.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$31K
- Abbott$27K
- Impulse Dynamics (USA) Inc.$150
What the payments were for
- Consulting fees$6,29610%
- Speaking & faculty fees$30,47548%
- Travel & lodging$13,84822%
- Food & beverage$13,21121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 56 | $24,209 |
| Medtronic(2 entities) | 84 | $14,650 |
| Siemens Medical Solutions USA, Inc. | 12 | $6,005 |
| Biosense Webster, Inc. | 35 | $5,107 |
| Philips North America LLC | 18 | $4,786 |
| Abbott | 69 | $4,277 |
| Biotronik Inc. | 17 | $2,331 |
| Atricure, Inc. | 30 | $879 |
| ZOLL Respicardia, Inc. | 2 | $477 |
| Impulse Dynamics (USA) Inc. | 4 | $331 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $307 |
| Altathera Pharmaceuticals LLC | 1 | $167 |
| E.r. Squibb & Sons, L.L.C. | 2 | $125 |
| Angiodynamics, Inc. | 2 | $46 |
| Bridgebio Pharma, Inc. | 1 | $39 |
| Johnson & Johnson | 2 | $36 |
| Cardiofocus, Inc. | 1 | $25 |
| Novartis | 1 | $22 |
| Cvrx, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$12,736
- ACUSON SC2000 Diagnostic Ultrasound System$3,400
- QC$2,612
- RESONATE EL ICD VR$2,416
- AVEIR$2,323
- EMBLEM MRI S-ICD$2,000
- Farapulse$1,875
- ACUSON Origin Diagnostic Ultrasound System$1,358
- Acticor$1,200
- Edora$1,200
- Rivacor$1,200
- Plexa$1,200
- Sentus$1,200
- Rhythmia Mapping System$1,060
- EVERA MRI XT DR SURESCAN$988
- remede System$477
- IGT D Therapy$470
- GlideLight$429
- AFFERA MAPPING SYSTEM$345
- Carto 3$334
How this compares
$63,831 in reported general payments places this provider in the 90th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $138,092 |
| EntrestoSacubitril/Valsartan | 16 | $10,393 |
| Mexiletine Hcl | 21 | $2,260 |
| Flecainide Acetate | 37 | $2,175 |
| Metoprolol Succinate | 99 | $1,988 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 29 | $608 |
| Amiodarone Hcl | 57 | $532 |
| Amlodipine Besylate | 15 | $245 |
| Sucralfate | 21 | $229 |
| Metoprolol Tartrate | 38 | $176 |
| Omeprazole | 13 | $81 |
| Carvedilol | 12 | $68 |
| Furosemide | 11 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $22 | $10,39316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Charlotte
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Sanjeev GulatiCharlotte$406K
- Richard BrowneCharlotte$379K
- Rohit MehtaCharlotte$189K
- Brian PowellCharlotte$160K
- Nicole Cyrille-SupervilleCharlotte$115K
- Noreen KellyCharlotte$84K
- Dermot PhelanCharlotte$76K
- Charles SimontonCharlotte$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.